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The extent of the combined tuberculosis (TB) and 
HIV epidemics in South Africa (SA) has created 
enormous operational challenges for a health service 
that has traditionally run vertical programmes for 
TB and HIV, with treatment delivered by different 
healthcare staff, often in separate facilities. This is particularly 
problematic for TB/HIV co-infected patients who need to access 
both services. 
In Cape Town, SA, the TB prevalence in HIV-positive patients 
initiating antiretroviral therapy (ART) has been reported to be as high 
as 25%,[1] while 51% of TB patients enrolled in the primary healthcare 
(PHC) TB treatment programme were recorded as co-infected with 
HIV in 2009.[2] In the developing world, TB is known to be the 
leading cause of death in HIV-positive patients[3,4] and in 2008 - 2009, 
a TB-case fatality of 6% was reported in the Cape Town PHC TB 
programme for HIV-positive TB patients.[5]
Despite the 2010 SA national ART guideline recommendations that 
ART should be initiated between 2 and 8 weeks after the initiation of 
TB treatment,[6] long referral delays have been reported between TB 
and ART facilities.[7,8] These delays could negatively influence TB 
treatment outcomes, particularly for co-infected patients with low 
CD4+ counts as the CAMELIA, STRIDE and SAPiT studies have 
documented. In these studies, death rates were significantly reduced 
for HIV/TB co-infected patients receiving TB treatment with CD4+ 
counts <50 cells/μl who initiated ART within 2 weeks after initiating 
TB treatment.[9-11]
In recent years, the SA National Department of Health (NDoH) 
has promoted the integration of TB and HIV services to facilitate easy 
access to healthcare services for TB/HIV co-infected patients and to 
rationalise resources.[12]
While the introduction of ART in facilities that provide TB 
treatment could be expected to decrease time from the initiation of 
TB treatment to the initiation of ART for co-infected patients and 
therefore impact favourably on TB death and default rates on an 
individual level, there are few reported data at healthcare facility level 
comparing TB treatment outcomes between integrated facilities that 
offer both TB treatment and ART and single-service facilities that 
only offer TB treatment.
This study evaluated the association of the integration of TB 
treatment and ART with TB treatment outcomes to determine 
whether integrated TB facilities, providing both TB and ART, had 
lower death and default rates than single TB service facilities that 
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Background. The combined tuberculosis (TB) and HIV epidemics in South Africa (SA) have created enormous operational challenges for a 
health service that has traditionally run vertical programmes for TB treatment and antiretroviral therapy (ART) in separate facilities. This 
is particularly problematic for TB/HIV co-infected patients who need to access both services. 
Objective. To determine whether integrated TB facilities had better TB treatment outcomes than single-service facilities in Cape Town, SA.
Methods. TB treatment outcomes were determined for newly registered, adult TB patients (aged ≥18 years) at 13 integrated ART/TB 
primary healthcare (PHC) facilities and four single-service PHC facilities from 1 January 2009 to 30 June 2010. A χ2 test adjusted for a cluster 
sample design was used to compare outcomes by type of facility.
Results. Of 13 542 newly registered patients, 10 030 received TB treatment in integrated facilities and 3 512 in single-service facilities. There 
was no difference in baseline characteristics between the two groups with HIV status determined for 9 351 (93.2%) and 3 227 (91.9%) 
patients, of whom 6 649 (66.3%) and 2 213 (63%) were HIV-positive in integrated facilities and single-service facilities, respectively. The 
median CD4+ count of HIV-positive patients was 152 cells/µl (interquartile range (IQR) 71 - 277) for integrated facilities and 148 cells/µl 
(IQR 67 - 260) for single-service facilities. There was no statistical difference in the TB treatment outcome profile between integrated and 
single-service facilities for all TB patients (p=0. 56) or for the sub-set of HIV-positive TB patients (p=0.58)
Conclusion. This study did not demonstrate improved TB treatment outcomes in integrated PHC facilities and showed that the provision of 
ART in the same facility as TB services was not associated with lower TB death and default rates. 
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referred patients off-site for ART. As the integration of facilities has 
been accompanied by the allocation of extra resources and staff, it 
was envisaged that integration could improve the general standard 
of care and, in turn, influence outcomes for both HIV-negative and 
-positive patients. 
We investigated the hypothesis that TB treatment outcomes would 
be better for all TB patients and for TB/HIV co-infected cases in 
facilities providing TB treatment and ART in one facility than in 
facilities that only provided TB treatment and required co-infected 
patients to access ART at a separate facility. 
Methods
Population and sample
The target population for this study comprised adult TB patients, aged 
≥18 years, who were registered in the national electronic TB register 
(ETR.net) in all PHC facilities that provided TB treatment in Cape 
Town over an 18-month period from 1 January 2009 to 30 June 2010.
Setting
During the study period, the Cape Town City Health Directorate and 
the Western Cape Department of Health provided TB treatment in 
99 PHC facilities in eight sub-districts in Cape Town, SA. Of these, 
68 provided TB treatment but not ART, while 31 provided integrated 
ART and TB treatment. All ART and TB services were provided 
free of charge. The TB treatment regimens during the study period 
were in accordance with the 2009 SA national TB management 
guideline.[13] New TB patients received fixed-dose combination tablets 
consisting of rifampicin, isoniazid, pyrazinamide and ethambutol for 
a 2-month intensive phase followed by rifampicin and isoniazid for 
a 4-month continuation phase. Treatment was received 7 days per 
week. Retreatment TB patients received 2 months of streptomycin 
5 days a week plus fixed-dose combination tablets consisting of 
rifampicin, isoniazid, pyrazinamide and ethambutol 7 days a week 
for a 3-month intensive phase followed by rifampicin, isoniazid and 
ethambutol 7 days a week for a 5-month continuation phase. 
All TB patients were routinely offered HIV testing. Eligibility for 
ART was determined for HIV-positive patients through CD4+ count 
testing and World Health Organization (WHO) disease staging. 
Consistent with the SA national ART guideline at the time of our 
study, patients were eligible for ART if they had a CD4+ count 
<200 cells/μl or WHO stage 4 disease.[14] These patients were offered 
ART in the same facility, if available, and if not, were referred to 
another facility to access ART. The recommended ART first-line 
treatment regimen for co-infected patients during the initial period 
of the study was stavudine or zidovudine, lamivudine and efavirenz.[14] 
In March 2010, near the end of the study period, this was changed to 
tenofovir, lamivudine and efavirenz.[6]
For the purpose of this study, integrated facilities were defined 
as facilities that provided both ART and TB treatment in the same 
building. Included in this definition were both partially integrated 
services that provided ART and TB treatment in different consulting 
rooms, and fully integrated services where both treatments were 
provided by the same clinician in the same consulting room.
Single-service facilities only provided TB treatment with patients 
being referred off-site for ART.
As this study aimed to examine the effect of integration of HIV 
and TB services, only high-burden TB facilities with a high HIV 
prevalence were included in the analysis. These were defined as 
facilities with a TB caseload >400 adult TB patients per year and a 
HIV prevalence >50% in all TB patients. Facilities were only included 
in the study if they had been either integrated or single service for 
the full study period. Patients who were initiated on treatment in 
hospital and were referred to a PHC clinic to continue their treatment 
were included in the analysis. However, to avoid possible duplication 
of cases, patients who were transferred between PHC clinics were 
excluded. Also excluded were patients with drug-resistant TB.
Study design
This was a retrospective cohort study using routine TB programme 
data. Facilities were considered as clusters with patients, linked to 
the facility over the period of sampling, as the individual-level data.
Data sources and management
Out of the 99 TB treatment facilities in Cape Town, 17 were either 
integrated or single service for the entire study period and met the 
inclusion criteria for high-burden facilities based on aggregated data 
for the 18-month period. Of these facilities, 13 were integrated and 
four were single-service facilities.
Individual patient data from these 17 facilities were extracted 
for this analysis from the ETR.net for Cape Town. This is a 
customised computer software program developed for the NDoH 
National TB Control Programme for the collection of individual 
patient information for routine monitoring and evaluation of the 
performance of the programme. TB cases are routinely recorded in 
a paper-based TB treatment register at PHC-facility level. These data 
are then captured in the ETR.net. For this study, data were extracted 
from ETR.net and all unique patient identifiers removed prior to 
analysis; the facility code was retained to ensure that individuals 
could be linked to facilities for the cluster analysis. 
Data on ART uptake were recorded in ETR.net, but since we 
were comparing sites that provided ART with sites that did not, the 
potential for bias in how ART uptake was recorded was high and 
these data were not considered reliable for comparative purposes. 
This prohibited an analysis of the direct association of TB treatment 
outcomes with ART uptake.
Definitions
HIV status
HIV-positive patients were defined as those with positive HIV 
tests recorded in ETR.net, or with unrecorded test results but were 
recorded to be receiving ART or co-trimoxazole or had CD4+ test 
results in ETR.net. HIV-negative patients were defined by recorded 
HIV-negative test results and no indication of ART or co-trimoxazole 
treatment in the ETR.net. All other patients were considered to be of 
unknown HIV status.
TB treatment outcomes
TB treatment outcomes used in this study were the outcomes recorded 
in ETR.net according to the internationally recommended WHO 
definitions of cure, completion, failure, death, default, transferred out 
and not evaluated.[15]
Statistical analysis
Descriptive features of the facilities by integration type were 
compared. The χ2 test, adjusted for a cluster sample design, was used 
to compare categorical variables such as the TB treatment outcome 
by type of facility. For continuous variables the median value was 
calculated for each facility and a two-sample Student’s t-test was used 
to compare these values between the two types of facilities (analysis 
at facility level). 
Ethics approval
During collection of data for ETR.net, TB patients are not requested 
to provide informed consent for the collection of data. For this 
RESEARCH
206       March 2014, Vol. 104, No. 3
analysis, the Cape Town City Health TB programme approved the 
use of an anonymised database of routinely collected TB data for 
research purposes. Ethics approval for the use of these data was 
obtained from the Ethics Advisory Group of the International Union 
Against Tuberculosis and Lung Disease who were requested to waive 
the requirement for informed consent as the analysis was to be 
carried out on routinely collected programmatic data with all patient 
identifiers removed. This study was also approved by the University 
of Cape Town Research Ethics Committee.
Results
A total of 16 885 patients were registered at the 17 facilities during the 
study period. Of these, 3 343 patients were excluded from the analysis 
as they were either <18 years of age or had been transferred between 
PHC TB facilities. The remaining 13 542 TB patients were included 
in this analysis. 
Baseline characteristics
All patients
The baseline demographics for all 13  542 patients were similar for 
patients in integrated facilities and single-service facilities (Table 1). 
The median age was 34 years (interquartile range (IQR) 28 - 42) and 
6 331 (46.7%) of the patients were female. HIV status was ascertained 
for 12 578 (92.9%) patients; 8 862 (65.4%) patients were HIV-positive, 
3 716 (27.4%) were HIV-negative and the HIV status was unknown 
for 964 (7.1%) patients. Of the total, 4  059 (30%) patients were 
classified as retreatment cases after a previous TB episode. A total of 
10  879 (80.3%) patients had pulmonary TB (PTB), 330 (2.4%) had 
both extrapulmonary (EPTB) and PTB, while 2 333 (17.2%) patients 
had EPTB. Of the 11  209 patients who had PTB or both PTB and 
EPTB, 5 557 (49.6%) were smear-positive, 5 019 (44.8%) were smear-
negative and 633 (5.6%) had no smear result recorded.
HIV-positive patients
The baseline demographics of the 8 862 HIV-positive patients were 
similar for patients in integrated facilities and single-service facilities 
(Table 2). Of all the HIV-positive patients, 4 855 (54.8%) were female 
and CD4+ counts were recorded for 8  411 (94.9%). The median 
CD4+ count was 151 cells/μl (IQR 70 - 273) and 5 291 (59.7%) had 
a CD4+ count <200 cells/μl. There was no difference in CD4+ count 
distribution between the two groups. Co-trimoxazole was provided 
to 8 466 (95.5%) of the HIV-positive patients. 
TB treatment outcomes
All patients
Fig. 1 compares the TB treatment outcome profile between integrated 
facilities and single-service facilities for all patients. The aggregated 
death and default rate for patients treated in all facilities was 16.4%. 
When compared across the two types of services, aggregated death 
and default rates were 17.2% (death 6.4%; default 10.8%) for 
integrated facilities and 14% (death 5.2%; default 8.8%) for single-
service facilities. 
The treatment success rate (aggregated cured and completion rates) 
was 74.1% for integrated facilities and 81.7% for single-service facilities. 
The treatment failure rate was similar for integrated facilities and 
single-service facilities (1.6% v. 1.7%, respectively). The transfer-out 
rate was 4.7% at integrated facilities and 1.9% at single-service facilities. 
There was no statistical difference in the treatment outcome profile 
between integrated and single-service facilities (p=0.56).
HIV-positive patients
Fig.  2 compares the treatment outcome profile between integrated 
facilities and single-service facilities for the sub-group of HIV-
positive patients. Aggregated death and default rates were 17.2% 
(death 7.3%; default 9.9%) for integrated facilities and 14.1% (death 
Table 1. Baseline characteristics of all TB patients aged ≥18 years registered at 13 integrated and four single-service facilities
Characteristic
Patients in PHC facilities
p-valueTotal Integrated Single-service 
Receiving TB treatment, n 13 542 10 030 3 512
Age (years), median (IQR) 34 (28 - 42) 33 (28 - 41) 34 (27 - 42) 0.45
Gender (female), n (%) 6 331 (46.7) 4 674 (46.6) 1 657 (47.2) 0.68
HIV status, n (%)
Positive 8 862 (65.4) 6 649 (66.3) 2 213 (63.0) 0.58
Negative 3 716 (27.4) 2 702 (26.9) 1 014 (28.9)
Unknown 964 (7.1) 679 (6.7) 285 (8.1)
Classification, n (%)
PTB 10 879 (80.3) 8 030 (80.0) 2 849 (81.1) 0.33
EPTB 2 333 (17.2) 1 721 (17.2) 612 (17.4)
PTB/EPTB 330 (2.4) 279 (2.8) 51 (1.5)
New 9 483 (70.0) 7 059 (70.4) 2 424 (69.0)
Retreatment 4 059 (30.0) 2 971 (29.6) 1 088 (31) 0.58
PTB and PTB/EPTB, n (%)
Smear-positive 5 557 (49.6) 4 110 (49.5) 1 447 (49.9) 0.72
Smear-negative 5 019 (44.8) 3 706 (44.6) 1 313 (45.3)
No smear 633 (5.6) 493 (5.9) 140 (4.8)
PHC = primary healthcare; TB = tuberculosis; IQR = interquartile range; PTB = pulmonary tuberculosis; EPTB = extrapulmonary tuberculosis.
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5.8%; default 8.3%) for single-service facilities. The treatment success 
rate was 73.2% for integrated facilities and 81.2% for single-service 
facilities. Treatment failure rates were similar for integrated facilities 
and single-service facilities (1.8% v. 1.6%, respectively). The transfer-
out rates was 5.1% at integrated facilities and 2.3% at single-service 
facilities. There was no statistical difference in the treatment outcome 
profile between integrated and single-service facilities (p=0.58).
Discussion
The results of this study, involving a large cohort of patients 
(N=13 542) who received TB treatment according to programmatic 
standards, reflect actual operational TB treatment outcomes in Cape 
Town. The study showed high unfavourable outcomes (aggregated 
death and a default rate of 16.4%) among all TB patients in high-
TB/HIV-burden PHC facilities. There was no significant difference 
in these outcomes between integrated facilities and single-service 
facilities. Overall single-service facilities had slightly better treatment 
outcomes with greater treatment success rates and lower death and 
default rates. However, there were more patients whose outcomes 
were not evaluated in the integrated facilities. 
Our results are similar to those of a much smaller study, which 
showed a decrease in time between the initiation of TB treatment 
and that of ART for TB/HIV co-infected patients when ART was 
introduced into routine TB services in Khayelitsha, Cape Town, but 
did not show an impact on TB treatment outcomes.[16] Other studies 
in Uganda and Kenya[17,18] have shown improvements in TB treatment 
success rates and a marked reduction in death and default rates after 
the integration of TB and ART services. However, both these studies 
reported higher death and default rates after integration of services 
than were observed in either the integrated or single-service facilities 
in our study. In Uganda, death and default rates were decreased from 
33% to 25% after the integration of services and in Kenya, the lost 
to follow-up rate decreased from 36% to 12.5% and death rates were 
reduced from 20% to 5.4% over a 5-year period after integration of 
services. While this shows an impressive improvement in outcomes, 
aggregated death and default rates remain high, ranging from 17.2% 
to 25% in the Cape Town, Kenyan and Ugandan studies despite 
integration of services.
In this study, the HIV prevalence in TB patients was very high 
(65.4%); almost 60% of patients had a CD4+ count <200 cells/μl and 
would have been eligible for ART under the 2004 SA national HIV 
treatment guideline. 
Study limitations 
A limitation of the study is that data on ART uptake and ART 
initiation dates were not uniformly collected in the TB services. We 
could, therefore, not perform a comparative study of ART uptake 
or determine whether the integration of services reduced the time 
Table 2. Baseline characteristics of HIV-positive TB patients aged ≥18 years registered at 13 integrated and four single-service 
facilities
Characteristic
Patients in PHC facilities
p-valueTotal Integrated Single-service 
Receiving TB treatment, n (%) 8 862 6 649 2 213
Age (years), median (IQR) 34 (28 - 40) 33 (28 - 40) 34 (28 - 40) 0.32
Gender (female), n (%) 4 855 (54.8) 3 629 (54.6) 1 226 (55.4) 0.40
CD4+ count (cells/μl), n (%)
Median (IQR) 151 (70 - 273) 152 (71 - 277) 148 (67 - 260) 0.96
≤50 1 504 (17) 1 117 (16.8) 387 (17.5) 0.70
51 - 100 1 441 (16.3) 1 083 (16.3) 358 (16.1)
101 - 200 2 346 (26.5) 1 779 (26.8) 567 (25.6)
201 - 350 1 809 (20.4) 1 355 (20.4) 454 (20.5)
>350 1 311 (14.8) 1 025 (15.4) 286 (12.9)
Missing 451 (5.1) 290 (4.4) 161 (7.3)
Classification, n (%)
PTB 6 725 (75.9) 5 017 (75.4) 1 708 (77.2) 0.37
EPTB 1 846 (20.8) 1 387 (20.9) 459 (20.7)
PTB/EPTB 291 (3.3) 245 (3.7) 46 (2.1)
New 6 138 (69.3) 4 639 (69.8) 1 499 (67.7) 0.39
Retreatment 2 724 (30.7) 2 010 (30.2) 714 (32.3)
PTB and PTB/EPTB, n (%)
Smear-positive 2 796 (39.9) 2 099 (39.7) 697 (39.7) 0.76
Smear-negative 3 747 (53.4) 2 790 (53) 957 (54.6)
No smear 473 (6.7) 373 (7.1) 100 (5.7)
Receiving co-trimoxazole, n (%)
Yes 8 446 (95.5) 6 349 (95.5) 2 117 (95.7) 0.84
No 396 (4.5) 300 (4.5) 96 (4.3)
PHC = primary healthcare; TB = tuberculosis; IQR = interquartile range; PTB = pulmonary tuberculosis; EPTB = extrapulmonary tuberculosis.
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between initiation of TB treatment and that of ART. Therefore 
this study could not determine the direct influence of ART on TB 
treatment outcomes.
Other studies in Cape Town have shown poor uptake of ART and 
long delays in time from initiation of TB treatment to that of ART 
in both integrated and single-service facilities. Pepper et al.[19] noted 
that 34/100 TB patients who were eligible for ART did not initiate 
treatment in an integrated TB and ART facility in Cape Town and 
reported a median time of 58 days from initiation of TB treatment to 
initiation of ART for co-infected patients. Nglazi et al.[20] reported that 
19.7% of ART-eligible TB patients did not initiate ART during their 
TB treatment in a large facility in Cape Town that had both ART and 
TB services on-site and recorded a median delay of 51 days between 
initiation of TB treatment and that of ART.
A further limitation of our study was that many of the single-
service facilities were excluded from the analysis due to either a small 
annual TB caseload or low co-infection rate. The study therefore 
compared four single-service facilities with a combined caseload of 
3 152 patients with 13 integrated facilities with a combined caseload 
of 10  030 patients. While this limited the power of the analysis to 
determine a statistically significant difference in outcomes, the trend 
of the analysis was for improved outcomes in the single-service 
facilities and not the integrated facilities. 
This study could also not determine the long-term influence of 
integrated services on mortality, as the analysis was restricted to 
the period of TB treatment. It is possible that integrated services 
would be better able to retain HIV-positive patients in care after 
TB treatment and therefore ensure better long-term outcomes for 
co-infected patients.
Conclusion
While the scale-up of ART in Cape Town has improved access to HIV 
treatment for TB/HIV co-infected patients, the high HIV prevalence, 
low median CD4+ counts and high death and default rates remain 
serious problems within the health services. This study has shown 
that in itself, the provision of ART in the same facility as TB services 
was not associated with improved TB treatment outcomes in the 
routine TB services. The exact reasons why the integration of services 
was not associated with better programmatic outcomes are not clear 
and warrant further operational research to inform services on how 
to improve integration. It is possible that an accurate recording 
of ART uptake and time taken to initiate ART, as part of routine 
indicators, would assist in assessing whether the provision of ART in 
TB facilities has actually improved access to ART. 
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